Daily non-political popular news in brief.
Daytrana provides significant effectiveness in both boys and girls with ADHD
05-23-2007 · EurekAlert!Shire plc announced that DAYTRANA, its ADHD patch medication, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association annual meeting. Few clinical studies have examined gender differences in the response to ADHD treatments.
Read more »
Keywords: daytrana, provides, significant, effectiveness, boys, girls, adhd, provide, boy, girl
« Previous | Next »
Similar news on "Daytrana provides significant effectiveness in both boys and girls with ADHD":
- DAYTRANA (methylphenidate transdermal system) provides individualized ADHD symptom management
10-27-2006 · EurekAlert!
Shire's Attention Deficit Hyperactivity Disorder patch, DAYTRANA tm (methylphenidate transdermal system) has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when removed earlier than the recommended nine hours. The ability to remove the patch earlier allows physicians the opportunity to manage potential late-day side effects, such as lack of appetite or difficulty sleeping, according to phase 3b trial results reported at a scientific child and adolescent psychiatry meeting in San Diego.
Similar news · Read more »
- Children's belly fat increases more than 65 percent since 1990s
11-06-2006 · EurekAlert!
Abdominal obesity increased more than 65 percent among boys and almost 70 percent among girls between 1988 and 2004. The finding of growing girth is significant because abdominal obesity has emerged as a better predictor of cardiovascular disease and type 2 diabetes risk than the more commonly used Body Mass Index, a weight-to-height ratio that can sometimes be misleading.
Similar news · Read more »
- 12-month study demonstrated tolerability and efficacy of Daytrana
05-23-2007 · EurekAlert!
Shire plc announced that Daytrana, the first and only non-oral medication approved for treatment of ADHD in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association annual meeting.
Similar news · Read more »
- Women Infected With Toxoplasmosis Are More Likely To Have Boys Than Girls
10-12-2006 · ScienceDaily
Women infected with dormant toxoplasmosis are more likely to give birth to boys than women who are Toxoplasma negative, according to research published in Springer's journal Naturwissenschaften this week. S. Kankova and colleagues from Charles University in the Czech Republic found that the presence of the parasite Toxoplasma gondii in the mothers' blood increased the likelihood that these women would give birth to a boy.
Similar news · Read more »
- First national review of pediatric soccer injuries finds 1.6 million ER visits over 13-year span
02-01-2007 · EurekAlert!
In this first national review of visits to US emergency rooms for soccer-related injuries the authors find significant age, gender disparities in injury rates, type and hospitalizations. Girls suffer more injuries than boys, and the youngest players (ages two - four years) are hospitalized more often than older players. Recommendations are made to improve youth soccer safety.
Similar news · Read more »
- Bad blood between boys and girls
10-11-2006 · EurekAlert!
Women infected with dormant toxoplasmosis are more likely to give birth to boys than women who are Toxoplasma negative, according to research published in Springer's journal Naturwissenschaften this week. S. Kankova and colleagues from Charles University in the Czech Republic found that the presence of the parasite Toxoplasma gondii in the mothers' blood increased the likelihood that these women would give birth to a boy.
Similar news · Read more »
- Latest data shows MabThera provides significant, sustained relief from symptoms of RA
06-13-2007 · EurekAlert!
New data presented at the EULAR meeting demonstrate that MabThera's effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.
Similar news · Read more »
- Long-term 12-month safety data on ADHD patch DAYTRANA
10-25-2007 · EurekAlert!
Shire plc announced that DAYTRANA (methylphenidate transdermal system), the ADHD patch, provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years, according to data from a 12-month study presented today at a major scientific and educational meeting of child and adolescent psychiatrists.
Similar news · Read more »
- Preschoolers with ADHD improve with low doses of medication
10-16-2006 · EurekAlert!
The first long-term, large-scale study designed to determine the safety and effectiveness of treating preschoolers who have attention deficit/hyperactivity disorder with methylphenidate has found that overall, low doses of this medication are effective and safe. However, the study found that children this age are more sensitive than older children to the medication's side effects and therefore should be closely monitored.
Similar news · Read more »
- Impact of exercise on body fat is different for boys and girls
03-28-2007 · EurekAlert!
The impact of exercise on body fat differs for boys and girls, suggests research published ahead of print in the British Journal of Sports Medicine.
Similar news · Read more »
